Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 17Unknown 3Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 108Carcinoma, Non-Small-Cell Lung 95Prostatic Neoplasms 58Multiple Myeloma 45Neoplasms 38Neoplasm Metastasis 33Ovarian Neoplasms 26Melanoma 24Urinary Bladder Neoplasms 23Lung Neoplasms 22Colorectal Neoplasms 22Recurrence 21Leukemia, Lymphocytic, Chronic, B-Cell 21Parkinson Disease 4, Autosomal Dominant Lewy Body 20Carcinoma, Renal Cell 20Carcinoma, Hepatocellular 17Triple Negative Breast Neoplasms 16Nasopharyngeal Carcinoma 16Lymphoma, Non-Hodgkin 16Stomach Neoplasms 15Leukemia, Myeloid, Acute 15Lymphoma 14Squamous Cell Carcinoma of Head and Neck 13Small Cell Lung Carcinoma 13Fallopian Tube Neoplasms 12Colonic Neoplasms 12Carcinoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11

Interventions

fezolinetant 1Tamoxifen 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × Hot Flashes × Clear all
NCT05587296 2026-05-06

OASIS-4

Bayer

Phase 3 Active not recruiting
474 enrolled 14 charts

Hot Flashes

NCT06440967 2026-04-06

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Astellas Pharma Inc

Phase 3 Active not recruiting
984 enrolled

Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡